Quantcast

Latest Actavis Stories

2014-04-29 08:34:05

BOSTON, April 29, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company") today announced financial results for the three-month period ended March 31, 2014. First Quarter 2014 Financial Highlights -- Total revenues grew 15% to $7.2 million compared to $6.3 million in the first quarter of 2013; -- Cash flow from operations increased to $0.9 million as compared with $0.7 million in the first quarter of 2013; -- Repurchased...

2014-04-28 16:31:49

DUBLIN, April 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex(®) (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Actavis maintains that the FDA improperly awarded sole exclusivity on generic Celebrex(®) to...

2014-04-24 08:36:01

DUBLIN, April 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Pfizer, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Celebrex(® )(celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Celebrex(®) is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Under the terms...

2014-04-21 08:26:22

DUBLIN, April 21, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that G. Frederick Wilkinson, President, Actavis Global R&D, will leave the Company effective April 25, 2014. The Company noted that Mr. Wilkinson has accepted the position of President and Chief Executive Officer at Impax Laboratories, Inc. (NASDAQ: IPXL). "Over the past five years, Fred has played an essential role in our evolution from a primarily generics company to a leading specialty...

2014-04-21 08:26:05

HAYWARD, Calif., April 21, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its Board of Directors has appointed G. Frederick Wilkinson as Impax's President and Chief Executive Officer effective April 29, 2014. Mr. Wilkinson, who previously served as President, Actavis Global Research and Development at Actavis plc succeeds Larry Hsu, Ph.D. who is retiring. "A long-time industry leader, Fred's extensive experience in managing generic, brand, R&D,...

2014-04-17 16:27:20

DUBLIN, April 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed. The...

2014-04-17 16:27:16

DUBLIN and NEW YORK, April 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis' pending acquisition of Forest. The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The effect of the second...

2014-04-17 08:27:47

BOSTON, April 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on April 29, 2014, to discuss financial results of the first quarter ended March 31, 2014. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows: Date: Tuesday, April 29, 2014 Time: 8:30 am EDT...

2014-04-15 08:29:42

DUBLIN, April 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess(®) FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets). Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess(®) FE under its pending Abbreviated New Drug...

2014-04-03 12:30:06

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013 The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related